TGR5 inhibitors and CRISPR/Cas9 techniques were used for both in vivo and in vitro targeted interventions, yielding favorable outcomes, as shown by improved liver fibrosis, mitigated liver inflammation, and augmented hepatic lipid metabolism. This evidence concerns the gene GPBAR1 and Hepatic fibrosis.